# EAU Guidelines

## Expert-Guided Poster Tour 1

### Saturday 17 March

**12:15 - 13:15**

**Location:** Green Area

**Chairs:**
- M. Burger, Regensburg (DE)
- J. N'Dow, Aberdeen (GB)

The Expert-Guided Poster Tour is a new innovative session type. The Tour aims to provide an interactive platform informing delegates on the real essentials and providing in-depth information on the different research projects. The Expert-Guided Poster Tour consists of two parts: The first part is reserved for poster viewing. The posters will be on display for 2 hrs before the start of the Guided Poster Tour. During the second part of the Tour, the two experts acting as moderators, will ask questions to poster presenters.

### PT001

**Key steps in conducting systematic reviews for underpinning clinical practice guidelines: Methodology of the European Association of Urology**

By: Knoll T., Omar M.I., MacLennan S., Hernández V., Canfield S., Yuan Y., Bruin M., Marconi L., Van Poppel H., N'Dow J., Sylvester R.

1. Sindelfingen-Boeblingen Medical Center, University of Tübingen, Dept. of Urology, Sindelfingen, Germany
2. University of Aberdeen, Academic Urology Unit, Aberdeen, United Kingdom
3. Hospital Universitario Fundacion Alcorcon, Dept. of Urology, Madrid, Spain
4. University of Texas McGovern Medical School, Division of Urology, Houston, United States of America
5. McMaster University, Dept. of Medicine, Hamilton, Canada
6. Radboud University Medical Center, Dept. of Urology, Nijmegen, Netherlands
7. Coimbra University Hospital, Dept. of Urology, Coimbra, Portugal
8. University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Dept. of Urology, Leuven, Belgium
9. EAU Guidelines Office, Brussels, Belgium

### PT002


1. General Teaching Hospital and 1st Faculty of Medicine, Charles University, Dept. of Urology, Prague, Czech Republic
2. Royal Free London NHS Foundation Trust, Dept. of Urology, London, United Kingdom
3. Hospital Universitario Fundación de Alcorcón, Dept. of Urology, Madrid, Spain
4. Hospital Motol and Second Faculty of Medicine, Charles University, Dept. of Urology, Prague, Czech Republic
5. Karitas-St. Josef Medical Center, University of Regensburg, Dept. of Urology, Regensburg, Germany
6. Hôpitaux Universitaires de l'Est-Parisien HUEP, Assistance Publique Faculty of Medicine Pierre et...
PT003

**Potential benefit of lymph node dissection during radical nephroureterectomy for upper tract urothelial carcinoma: A systematic review by the European Association of Urology Guidelines Panel on non-muscle-invasive bladder cancer**


1 Fundación Instituto Valenciano de Oncología, Dept. of Urology, Valencia, Spain;
2 University of Rennes, Dept. of Urology, Rennes, France;
3 La Pitié-Salpêtrière Hospital, Assistance-Publique Hôpitaux de Paris, Academic Dept. of Urology, Paris, France;
4 Radboud University Nijmegen Medical Centre, Dept. of Urology, Nijmegen, Netherlands, The;
5 McMaster University, Dept. of Medicine, Division of Gastroenterology, Hamilton, Canada;
6 Hospital Motol, Second Faculty of Medicine, Charles University, Dept. of Urology, Prague, Czech Republic;
7 HELIOS Agnes-Karll-Krankenhaus, Dept. of Urology, Bad Schewartau, Germany;
8 Caritas St. Josef Medical Centre, University of Regensburg, Dept. of Urology, Regensburg, Germany;
9 La Pitié-Salpêtrière Hospital, UPMC, Dept. of Pathology, Paris, France;
10 University of Turin, Dept. of Urology, Turin, Italy;
11 University of Aberdeen, Academic Urology Unit, Aberdeen, United Kingdom;
12 North Hampshire Hospital, Dept. of Urology, Basingstoke, United Kingdom;
13 Fundació Puigvert, Universidad Autónoma de Barcelona, Dept. of Urology, Barcelona, Spain;
14 Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Dept. of Surgical Oncology, Amsterdam, Netherlands, The;
15 European Association of Urology Guidelines Office, Brussels, Belgium;
16 Medical University of Graz, Dept. of Urology, Graz, Austria;
17 Medical University of Vienna, Vienna General Hospital, Dept. of Urology, Vienna, Austria;
18 La Pitié-Salpêtrière Hospital, Assistance-Publique Hôpitaux de Paris, Dept. of Urology, Paris, France

PT004

**How to resolve discrepancies when findings from randomized controlled trials and meta-analyses disagree?**

By: *Sylvester R.J.*, 1 Canfield S.E. 2, Lam T.B.L. 3, Marconi L. 4, MacLennan S. 3, Yuan Y. 5, MacLennan G. 6, Norrie J. 6, Omar M.I. 7, Bruins H.M. 8, Hernández V. 9, Plass
Oncological outcomes of laparoscopic nephroureterectomy versus open radical nephroureterectomy for upper tract urothelial carcinoma: An European Association of Urology Guidelines systematic review


1CHU Rennes, Dept. of Urology, Rennes, France, 2La Pitié-Salpêtrière Hospital, Dept. of Urology, Paris, France, 3Fundación Instituto Valenciano de Oncología, Dept. of Urology, Valencia, Spain, 4Radboud University Nijmegen Medical Centre, Dept. of Urology, Nijmegen, Netherlands, The, 5McMaster University, Dept. of Medicine, Division of Gastroenterology, Hamilton, Canada, 6University of Aberdeen, Academic Urology Unit, Aberdeen, United Kingdom, 7Aberdeen Royal Infirmary, Dept. of Urology, Aberdeen, United Kingdom, 8Hospital Motol, Second Faculty of Medicine, Charles University, Dept. of Urology, Prague, Czech Republic, 9Tenon Hospital, Dept. of Pathology, Paris, France, 10Medical University of Graz, Dept. of Urology, Graz, Austria, 11European Association of Urology Guidelines Office, Brussels, 12Caritas St. Josef Medical Centre, University of Regensburg, Dept. of Urology, Regensburg, Germany, 13North Hampshire Hospital, Dept. of Urology, Basingstoke, United Kingdom, 14Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Dept. of Surgical Oncology, Amsterdam, Netherlands, The, 15University of Turin, Dept. of Urology, Turin, Italy, 16Fundació Puigvert, Universidad Autónoma de Barcelona, Dept. of Urology, Barcelona, Spain, 17Vienna General Hospital, Dept. of Urology, Vienna, Austria

What are core outcome sets, how should they be developed and why are they essential for urology?

By: MacLennan S. 1, Williamson P.R. 2, Lam T.B.L. 1, Omar M.I. 1, Canfield S. 3, Marconi L. 4, N'Dow J. 1, Yuan Y. 5, Sylvester R. 6

1University of Aberdeen, Academic Urology Unit, Aberdeen, United Kingdom, 2University of Liverpool, Dept. of Biostatistics, Liverpool, United Kingdom, 3University of Texas McGovern Medical School, Division of Urology, Houston, United States of America, 4Coimbra University Hospital, Dept. of Urology, Coimbra, Portugal, 5McMaster University, Dept. of Medicine, Hamilton, Canada, 6EAU Guidelines Office, Brussels, Belgium
PT007

A core outcome set for localised prostate cancer effectiveness trials

By: MacLennan S.¹, Williamson P.R.², MacLennan S.¹, N'Dow J.¹, Lam T.B.L.¹
¹University of Aberdeen, Academic Urology Unit, Aberdeen, United Kingdom, ²University of Liverpool, Dept. of Biostatistics, Liverpool, United Kingdom

PT008

What is the negative predictive value of multiparametric magnetic resonance imaging in excluding prostate cancer at biopsy? A systematic review and meta-analysis

By: Moldovan P.¹, Van Den Broeck T.², Sylvester R.³, Marconi L.⁴, Bellmunt J.⁵, Van Den Bergh R.C.N.⁶, Bolla M.⁷, Briers E.⁸, Cumberbatch M.G.⁹, Fossati N.¹⁰, Gross T.¹¹, Henry A.M.¹², Joniau S.², Van Der Kwast T.H.¹³, Matveev V.B.¹⁴, Van Der Poel H.G.¹⁵, De Santis M.¹⁶, Schoots I.G.¹⁷, Wiegel T.¹⁸, Yuan C.Y.¹⁹, Cornford P.²⁰, Mottet N.²¹, Lam T.B.²², Rouvière O.²³
¹Hospices Civils de Lyon, Hôpital Edouard Herriot, Dept. of Urinary and Vascular Radiology, Lyon, France, ²University Hospitals Leuven, Dept. of Urology, KU Leuven, Laboratory of Molecular Endocrinology, Leuven, Belgium, ³European Association of Urology Guidelines Office, Brussels, Belgium, ⁴Coimbra University Hospital, Dept. of Urology, Coimbra, Portugal, ⁵Dana-Farber Cancer Institute, Bladder Cancer Center, Harvard Medical School, Boston, United States of America, ⁶Netherlands Cancer Institute, Dept. of Urology, Amsterdam, Netherlands, The, ⁷CHU Grenoble, Dept. of Radiation Therapy, Grenoble, France, ⁸Patient advocate, Hasselt, Belgium, ⁹University of Sheffield, Academic Urology Unit, Sheffield, United Kingdom, ¹⁰IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Division of Oncology/Unit of Urology, Milan, Italy, ¹¹University of Bern, Inselspital, Dept. of Urology, Bern, Switzerland, ¹²St. James's University Hospital and University of Leeds, Leeds Cancer Centre, Leeds, United Kingdom, ¹³Erasmus Medical Center, Dept. of Pathology, Rotterdam, Netherlands, The, ¹⁴N.N. Blokhin Cancer Research Center, Moscow, Russia, ¹⁵Netherlands Cancer Institute, Dept. of Urology, Amsterdam, Netherlands, The, ¹⁶University of Warwick, Cancer Research Centre, Coventry, United Kingdom, ¹⁷Erasmus MC, Dept. of Radiology & Nuclear Medicine, Rotterdam, Netherlands Cancer Institute, Dept. of Radiology, Amsterdam, Netherlands, The, ¹⁸University Hospital Ulm, Dept. of Radiation Oncology, Ulm, Germany, ¹⁹McMaster University, Division of Gastroenterology and Cochrane UGPD Group, Dept. of Medicine, Health Sciences Centre, Hamilton, Canada, ²⁰Royal Liverpool and Broadgreen Hospitals NHS Trust, Liverpool, United Kingdom, ²¹University Hospital, Dept. of Urology, Saint-Étienne, France, ²²University of Aberdeen, Academic Urology Unit, Aberdeen, United Kingdom, ²³Hospices Civils de Lyon, Hôpital Edouard Herriot, Dept. of Urinary and Vascular Radiology, Lyon, France

PT009

The benefits and harms of different extents of lymph node dissection during radical prostatectomy for prostate cancer: A systematic review

By: Fossati N.¹, Willemse P.-P.², Van Den Broeck T.³, Yuan Y.⁴, Briers E.⁵, Bellmunt J.⁶, Bolla M.⁷, Cornford P.⁸, De Santis M.⁹, MacPepple E.¹⁰, Henry A.M.¹¹, Matveev S.¹², Van Der Poel H.G.¹³, Van Der Kwast T.¹⁴, Rouvière O.¹⁵, Wiegel T.¹⁶, Lam T.¹⁰, Mottet N.¹⁷, Joniau S.³
¹IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Division of
PT010

Systematic review of quality of life outcomes after primary treatment for clinically localised prostate cancer


1Leto Hospital, Dept. of Urology, Athens, , 2Wrightington, Wigan and Leigh NHS Foundation Trust, Dept. of Urology, Wigan, United Kingdom, 3Netherlands Cancer Institute, Dept. of Urology, Amsterdam, Netherlands, The, 4University of Warwick, Clinical Trials Unit, Coventry, United Kingdom, 5Dana-Farber Cancer Institute, Bladder Cancer Center, Boston, United States of America, 6University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, 7Royal Liverpool and Broadgreen Hospitals NHS Trust, Liverpool, United Kingdom, 8University of Sheffield, Academic Urology Unit, Sheffield, United Kingdom, 9IRCCS Ospedale San Raffaele, Unit of Urology/Division of Oncology, Milan, Italy, 10University of Bern, Inselspital, Dept. of Urology, Bern, Switzerland, 11St. James’s University Hospital and University of Leeds, Leeds Cancer Centre, Leeds, United Kingdom, 12CHU Grenoble, Dept. of Radiation Therapy, Grenoble, France, 13Patient representative, Hasselt, Belgium, 14University of Aberdeen, Academic Urology Unit, Aberdeen, United Kingdom, 15Cardiff University, School of Medicine, Health Park, Wales Cancer Bank, Cardiff, United Kingdom, 16University Hospital, Dept. of Urology, Saint-Etienne, France, 17Hospices Civils de Lyon, Radiology Department, Edouard Herriot Hospital, Lyon, France, 18Erasmus MC University Medical Center, Dept. of Radiology & Nuclear Medicine, Rotterdam, Netherlands, The, 19University Hospital Ulm, Dept. of Radiation Oncology, Ulm, Germany, 20University Hospital Groningen, Dept. of Urology, Groningen, Netherlands, The, 21 Dept. of Medicine, Hamilton, Canada, 22Sheffield Hallam University, Faculty of Health and Wellbeing, Sheffield, United Kingdom
A systematic review and meta-analysis comparing the effectiveness and adverse effects of different systemic treatments for non-clear cell renal cell carcinoma


1 Cabueñes Hospital, Dept. of Urology, Gijón, Spain, 2 Sunderby Hospital, Dept. of Urology, Sunderby, Sweden, 3 University Hospital Hamburg Eppendorf, Dept. of Urology, Hamburg, Germany, 4 Coimbra University Hospital, Dept. of Urology, Coimbra, Portugal, 5 University of Aberdeen, Academic Urology Unit, Aberdeen, United Kingdom, 6 Institut Gustave Roussy, Dept. of Cancer Medicine, Villejuif, France, 7 University of Rennes, Dept. of Urology, Rennes, France, 8 University of Texas Medical School at Houston, Division of Urology, Houston, United States of America, 9 Skåne University Hospital, Dept. of Urology, Malmö, Sweden, 10 Patient Advocate International Kidney Cancer Coalition (IKCC), University Medical Centre Utrecht, Dept. of Nephrology and Hypertension, Utrecht, Netherlands, The, 11 Faculty Hospital and Faculty of Medicine in Pilsen, Charles University, Dept. of Urology, Prague, Czech Republic, 12 Hanover Medical School, Dept. of Urology and Urologic Oncology, Hanover, Germany, 13 University Hospital Schleswig-Holstein, Dept. of Urology, Lübeck, Germany, 14 The Royal Free NHS Trust and Barts Cancer Institute, Queen Mary University of London, London, United Kingdom, 15 Ludwig-Maximilians University, Dept. of Urology, Munich, Germany, 16 Maggiore della Carità Hospital, University of Eastern Piedmont, Division of Urology, Novara, Italy, 17 Umeå University, Dept. of Surgical and Perioperative Sciences, Urology and Andrology, Umeå, Sweden, 18 Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Dept. of Urology, Amsterdam, Netherlands, The

Systematic review of the performance of non-invasive tests in diagnosing bladder outlet obstruction in men with lower urinary tract symptoms


1 Guy’s and St Thomas' NHS Foundation Trust, Dept. of Urology, London, United Kingdom, 2 Freeman Hospital, Dept. of Urology, Newcastle upon Tyne, United Kingdom, 3 Klinikum Sindelfingen-Böblingen, Dept. of Urology, Sindelfingen, Germany, 4 University of Aberdeen, Academic Urology Unit, Aberdeen, United Kingdom, 5 Asklepios Hospital Harburg, Dept. of Urology, Hamburg, Germany, 6 University Hospital Bonn, Dept. of Urology, Bonn, Germany, 7 University of Bristol, School of Clinical Sciences, Bristol, United Kingdom, 8 University of Florence, AOUC – Careggi Hospital, Dept. of Urology, Florence, Italy, 9 Ludwig-Maximilians-University Munich, Dept. of Urology, Munich, United Kingdom, 10 Kaiser Franz Josef Spital, Dept. of Urology, Vienna, Austria, 11 University General Hospital of Heraklion, University of Crete Medical School, Dept. of Urology, Heraklion, Greece, 12 University of Helsinki and Helsinki University Hospital, Depts. of Urology and Public Health, Helsinki, Finland, 13 Faculty of Medicine, School of Health Sciences, University of Thessaly, Dept. of Urology, Larissa, Greece
**PT013**

Is nonoperative management the best first-line option for high-grade renal trauma? A systematic review

By: Sujenthiran A. 1, Elshout P.J. 2, Veskimae E. 3, Abu-Ghanem Y. 4, MacLennan S. 5, Yuan Y. 6, Serafetindis E. 7, Sharma D.M. 1, Kitrey N.D. 4, Djakovic N. 6, Lumen N. 2, Kuehhas F.E. 9, Summerton D.J. 10

1St George’s Healthcare NHS Trust, Dept. of Urology, London, United Kingdom, 2Ghent University Hospital, Dept. of Urology, Ghent, Belgium, 3Tampere University Hospital, Dept. of Urology, Tampere, Finland, 4Chaim Sheba Medical Centre, Dept. of Urology, Tel-Hashomer, Israel, 5University of Aberdeen, Academic Urology Unit, Aberdeen, United Kingdom, 6Health Science Centre, McMaster University, Dept. of Medicine, Hamilton, Canada, 7Asklipieion General Hospital, Dept. of Urology, Athens, Greece, 8Muhldorf General Hospital, Dept. of Urology, Muhldorf am Inn, Germany, 9Private Office, Vienna, Austria, 10University Hospitals of Leicester NHS Trust, Dept. of Urology, Leicester, United Kingdom

**PT014**

The risk of tumour recurrence in patients undergoing renal transplantation for end-stage renal disease after previous treatment for a urological cancer: A systematic review


1Aix-Marseille University, Marseille, France, 2Hospital Universitario Ramón y Cajal, Alcalá University, Dept. of Urology, Madrid, Spain, 3Radboudumc, Dept. of Urology, Nijmegen, Netherlands, The, 4Charité Universitätsmedizin Berlin, Dept. of Nephrology, Berlin, Germany, 5Coimbra University Hospital, Dept. of Urology and Renal Transplantation, Coimbra, Portugal, 6Hospital General Universitario Gregorio Marañón, Dept. of Urology, Madrid, Spain, 7Guy's and St Thomas' Hospital, Dept. of Urology and Renal Transplantation, London, United Kingdom, 8Medical University of Vienna, Clinical Institute of Pathology, Vienna, Austria, 9St George's Hospital, Dept. of Urology and Renal Transplantation, London, United Kingdom, 10Guy's and St Thomas' Hospital, Dept. of Urology and Renal Transplantation, London, United Kingdom, 11McMaster University, Dept. of Medicine, Health Science Centre, Hamilton, Canada, 12Fundacion Puigvert, University Autonoma of Barcelona, Dept. of Urology, Barcelona, Spain

**PT015**

Testicular tumour size and rete testis invasion as prognostic factors for the risk of relapse of clinical stage I seminoma testis patients under surveillance: A systematic review by the Testicular Cancer Guidelines Panel

By: Boormans J.L. 1, Mayor de Castro J. 2, Marconi L. 3, Yuan Y. 4, Laguna Pes M.P. 5, Bokemeyer C. 6, Nicolai N. 7, Algafo F. 8, Oldenburg J. 9, Albers P. 10

1Erasmus MC Cancer Institute, Dept. of Urology, Rotterdam, Netherlands, The, 2Hospital Gregorio Marañón, Dept. of Urology, Madrid, Spain, 3Centro Hospitalar e Universitário de Coimbra, Dept. of Urology and Renal Transplantation, Coimbra, Portugal, 4Health Sciences Centre, McMaster University, Division of Gastroenterology and Cochrane UGPD Group, Department of Medicine, Hamilton, Canada, 5AMC University Hospital, Dept. of Urology, Amsterdam, Netherlands, The, 6University Hospital Eppendorf, Dept. of Internal
Scientific Programme - EAU18 Copenhagen

Medicine II, Oncology, Hematology and Stem Cell Transplantation with Section
Pneumology, Hamburg, Germany, 7Fondazione IRCCS Istituto Nazionale Tumori, Milan,
Italy, 8Fundación Puigvert, Universitat Autònoma de Barcelona, Dept. of Pathology,
Barcelona, Spain, 9of Oncology, Akershus University Hospital, Lørenskog, Norway and
University of Oslo, Oslo, Norway, 10Düsseldorf University Hospital, Heinrich-Heine-
University Düsseldorf, Dept. of Urology, Düsseldorf, Germany